nach oben

Erschienen in:

01.07.2009 | ORIGINAL CONTRIBUTION

Olanzapine compared to quetiapine in adolescents with a first psychotic episode

verfasst von: Celso Arango, MD, PhD, Olalla Robles, PhD, Mara Parellada, MD, PhD, David Fraguas, MD, Ana Ruiz-Sancho, MD, Oscar Medina, MD, Arantzazu Zabala, PhD, Igor Bombín, PhD, Dolores Moreno, MD, PhD

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

To compare the efficacy, safety, and tolerability of olanzapine and quetiapine in adolescents with first episode psychosis.

Method

Fifty adolescents (age 16 ± 1.25) with a first episode of psychosis were randomized to quetiapine or olanzapine in a 6-month open label study. Efficacy and side effect scales, as well as vital signs and laboratory data were recorded at baseline, 7, 15, 30, 90, and 180 days (end of study).

Results

Out of the total sample included in the study, 32 patients completed the trial (quetiapine n = 16, olanzapine n = 16). Patients in both treatment groups had a significant reduction in all clinical scales with the exception of the negative scale of the Positive and Negative Symptom Scale (PANSS) for olanzapine and the general psychopathology scale of the PANSS for quetiapine. The only difference between treatment arms on the clinical scales was observed on the patients’ strength and difficulties questionnaire (SDQ) scale, with greater improvement for olanzapine. Patients on olanzapine gained 15.5 kg and patients on quetiapine gained 5.5 kg.

Conclusion

Olanzapine and quetiapine reduced psychotic symptoms in this adolescent sample. Patients on olanzapine gained significantly more weight. Side effects with both drugs seemed to be more prevalent than those reported in adult studies.

Arango C, Parellada M, Moreno DM (2004) Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 14:S471–S479PubMedCrossRef

Barnes TR (2003) The Barnes Akathisia rating scale—revisited. J Psychopharmacol 17:365–370PubMedCrossRef

Conley RR, Kelly DL (2005) Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci 42:51–60PubMed

Correll CU, Malhotra AK (2004) Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 174:477–489CrossRef

Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK (2006) Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 15:177–206PubMedCrossRef

Charach A, Volpe T, Boydell KM, Gearing RE (2008) A theoretical approach to medication adherence for children and youth with psychiatric disorders. Harv Rev Psychiatry 16:126–135PubMedCrossRef

Fedorowicz VJ, Fombonne E (2005) Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol 19:533–550PubMedCrossRef

Findling RL (2005) Update on the treatment of bipolar disorder in children and adolescents. Eur Psychiatry 20:87–91PubMedCrossRef

Findling RL, McNamara NK, Youngstrom EA, Branicky LA, Demeter CA, Schulz SC (2003) A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 42:170–175PubMedCrossRef

10.

Fraguas D, Merchan-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giraldez M, Arango C (2008) Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69:1166–1175PubMedCrossRef

11.

Goodman R (1999) The extended version of the strengths and difficulties questionnaire as a guide to child psychiatric caseness and consequent burden. J Child Psychol Psychiatry 40:791–799PubMedCrossRef

12.

Goodman R (1997) The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry 38:581–586PubMedCrossRef

13.

Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G, Kikinzon L, Tyano S, Weizman R, Ratzoni G (2003) Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 110:545–560PubMedCrossRef

14.

Guy W (1976) Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology revised. National Institute of Mental Health, Rockville

15.

Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296PubMed

16.

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087PubMedCrossRef

17.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097PubMedCrossRef

18.

Kay SR, Opler LA, Lindenmayer JP (1989) The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl, pp 59–67

19.

Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA (2007) Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1061–1071PubMedCrossRef

20.

Kopala LC, Good KP, Milliken H, Buiteman C, Woodley H, Rui Q, Whitehorn D, Love L, Balshaw R, Kiss I, Honer WG (2006) Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr Res 81:29–39PubMedCrossRef

21.

Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL (1996) Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090–1097PubMed

22.

Laita P, Cifuentes A, Doll A, Llorente C, Cortes I, Parellada M, Moreno D, Ruiz-Sancho A, Graell M, Arango C (2007) Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 17:487–502PubMedCrossRef

23.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223PubMedCrossRef

24.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396–1404PubMedCrossRef

25.

Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100PubMedCrossRef

26.

McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K (2003) Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 13:75–82PubMedCrossRef

27.

McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE (2000) Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252–260PubMed

28.

Mozes T, Ebert T, Michal SE, Spivak B, Weizman A (2006) An Open-label randomized comparsion of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 16:393–403PubMedCrossRef

29.

Mozes T, Toren P, Chernauzan N, Mester R, Yoran-Hegesh R, Blumensohn R, Weizman A (1994) Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:65–70PubMedCrossRef

30.

Naber D, Karow A, Lambert M (2005) Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl, pp 29–34

31.

Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B (2001) Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 50:79–88PubMedCrossRef

32.

Olfson M, Blanco C, Liu L, Moreno C, Laje G (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679–685PubMedCrossRef

33.

Purdon SE, Snaterse M (1998) Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia. Can J Psychiatry 43:84–85PubMed

34.

Sengupta SM, Klink R, Stip E, Baptista T, Malla A, Joober R (2005) Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders. Schizophr Res 80:131–133PubMedCrossRef

35.

Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983) A children’s global assessment scale (CGAS). Arch Gen Psychiatry 40:1228–1231PubMed

36.

Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M (2001) A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415–424PubMedCrossRef

37.

Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721–730PubMedCrossRef

38.

Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133–145PubMedCrossRef

39.

Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19PubMedCrossRef

40.

Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL (2002) Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53:239–248PubMedCrossRef

41.

Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando ML, Senthilal S (2007) Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 96:146–155PubMedCrossRef

42.

Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435PubMedCrossRef

Titel: Olanzapine compared to quetiapine in adolescents with a first psychotic episode
verfasst von: Celso Arango, MD, PhD
Olalla Robles, PhD
Mara Parellada, MD, PhD
David Fraguas, MD
Ana Ruiz-Sancho, MD
Oscar Medina, MD
Arantzazu Zabala, PhD
Igor Bombín, PhD
Dolores Moreno, MD, PhD
Publikationsdatum: 01.07.2009
Verlag: Steinkopff-Verlag
Erschienen in: European Child & Adolescent Psychiatry / Ausgabe 7/2009
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-009-0749-5

Neu im Fachgebiet Psychiatrie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Olanzapine compared to quetiapine in adolescents with a first psychotic episode